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 2012 EMBO Molecular MedicineSecreted Semaphorin 3E (Sema3E) promotes cancer cell invasiveness and meta-
static spreading. The pro-metastatic activity of Sema3E is due to its proteolytic
fragment p61, capable of transactivating the oncogenic tyrosine kinase ErbB2 that
associates with the Sema3E receptor PlexinD1 in cancer cells. Here, we show that a
mutated, uncleavable variant of Sema3E (Uncl-Sema3E) binds to PlexinD1 like
p61-Sema3E, but does not promote the association of PlexinD1 with ErbB2 nor
activates the ensuing signalling cascade leading to metastatic spreading. Further-
more, Uncl-Sema3E competes with endogenous p61-Sema3E produced by tumour
cells, thereby hampering their metastatic ability. Uncl-Sema3E also acts indepen-
dently as a potent anti-angiogenic factor. It activates a PlexinD1-mediated
signalling cascade in endothelial cells that leads to the inhibition of adhesion
to extracellular matrix, directional migration and cell survival. The putative
therapeutic potential of Uncl-Sema3E was validated in multiple orthotopic or
spontaneous tumour models in vivo, where either local or systemic delivery of Uncl-
Sema3E-reduced angiogenesis, growth and metastasis, even in the case of tumours
refractory to treatment with a soluble vascular endothelial growth factor trap.
In summary, we conclude that Uncl-Sema3E is a novel inhibitor of tumour
angiogenesis and growth that concomitantly hampers metastatic spreading.INTRODUCTION
Semaphorins are evolutionarily conserved signalling molecules,
initially identified as axonal guidance cues, and now thought to
regulate a wide range of developmental and pathological
processes including angiogenesis and cancer progression
(Capparuccia & Tamagnone, 2009; Neufeld & Kessler, 2008;, University of Torino
esearch and Vascular
logy, Haifa, Israel
972 4 8523672;
þ39 011 9933225;Zhou et al, 2008). Semaphorin receptors are found in the
families of plexins and neuropilins. The associated signalling
pathways start to be understood and often involve negative
regulation of monomeric GTPases controlling cell-substrate
adhesion and cell migration. However, in addition to this,
certain semaphorins and plexins can trigger the activation of
plexin-associated tyrosine kinases in a cell context-dependent
manner, leading to activation of distinctive signalling cascades
that promote cell migration and invasive growth (Franco &
Tamagnone, 2008). Due to their emerging role in tumour
angiogenesis, tumour growth and metastasis, semaphorins
appear to be promising molecular targets controlling cancer
progression. Intriguingly, certain semaphorins can regulate both
cancer cells and stromal cells in the tumour microenvironment,
leading to concomitant functional effects in vivo (reviewed by
Capparuccia & Tamagnone, 2009).
Semaphorin 3E (Sema3E) has been found inmetastatic tumour
cells (Christensen et al, 1998, 2005) and it was then shown to be
crucially involved in developmental and post-ischemic angiogen-EMBO Mol Med 4, 234–250 www.embomolmed.org
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Figure 1. Uncl-Sema3E is unable to trigger ErbB2
activation and cancer cell migration.
A. Schematic diagram summarizing Sema3E iso-
forms: the full-length precursor of 87 kDa (p87),
the proteolytically cleaved fragment p61 and
the mutated uncleavable molecule (Uncl-esis as an endothelial-repelling signal (Fukushima et al, 2011; Gu
et al, 2005; Kim et al, 2011). Moreover, Sema3E can differentially
regulate distinctive neuronal populations, mediating either
axonal repulsion or attraction (Chauvet et al, 2007). Notably,
unlike other class 3 secreted semaphorins, Sema3E binds directly
to the PlexinD1 receptor and is not dependent on neuropilin co-
receptors (Gu et al, 2005). We have recently shown that Sema3E-
PlexinD1 signalling triggers two distinct pathways in cancer cells
and in cells of the tumour microenvironment (Casazza et al,
2010). On one hand, endothelial cells and developing vessels are
typically repelled by Sema3E, acting as an anti-angiogenic factor
through PlexinD1 signalling (Casazza et al, 2010); this pathway
seems to implicate an endothelial-specific regulation of the
GTPases Arf6 (Sakurai et al, 2010) and RhoJ (Fukushima et al,
2011), affecting integrin-mediated adhesion and cytoskeletal
remodelling. In cancer cells instead, Sema3E signalling promotes
invasiveness and metastatic spreading in vivo, and this activity is
mediated by the trans-activation of erythroblastic leukemia viral
oncogene homolog 2 (ErbB2)-epidermal growth factor receptor
(EGFR) oncogenic tyrosine kinase receptors (Casazza et al, 2010).
In addition, Sema3E levels in human tumour samples were found
to correlate with metastatic progression (Casazza et al, 2010).
Therefore, although Sema3E could strongly inhibit angiogenesis
in vivo, its potential application for the blockade of tumour
progression is actually excluded by its intrinsic pro-metastatic
activity.
Interestingly, it has been shown that the functional activity of
class 3 semaphorins is subject to regulation by proteolytic
cleavage due to furin-like pro-protein-convertases (Adams et al,
1997; Christensen et al, 2005; Kutschera et al, 2011; Varshavsky
et al, 2008). While in most cases this processing was reported to
blunt semaphorin signalling, in the case of Sema3E, it is actually
required for revealing its pro-metastatic activity in cancer cells
(Christensen et al, 2005). In fact, the proteolytic fragment p61 is
the active and predominant form of Sema3E found in invasive
and metastatic cancer cells (Casazza et al, 2010).B
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www.embomolmed.org EMBO Mol Med 4, 234–250In this study, we have employed a point-mutated Sema3E
isoform resistant to furin-mediated cleavage, named Uncl-
Sema3E, in order to dissect the two distinctive signalling
cascades mediated by this semaphorin in cancer progression. In
fact, Uncl-Sema3E displayed potent endothelial-repelling and
anti-angiogenic activities, thereby dramatically suppressing
tumour growth; and yet, it was devoid of the pro-metastatic
effect of p61-Sema3E. We found that Uncl-Sema3E competes
with p61-Sema3E for binding to the receptor; thus, it can
efficiently block the signalling of endogenous p61 released by
cancer cells and blunt its autocrine pro-invasive and pro-
metastatic activity. We have furthermore demonstrated the
potential therapeutic efficacy of the systemic delivery of Uncl-
Sema3E, acting as a dual anti-angiogenic and anti-metastatic
molecule in multiple preclinical models of cancer progression
in mice.RESULTS
Full-length uncleaved Sema3E antagonizes mature p61-
Sema3E and blocks its pro-metastatic signalling in cancer cells
Sema3E signalling in tumour cells promotes invasion and
metastasis, but these activities crucially depend on its
proteolytic maturation into the smaller fragment p61 (Chris-
tensen et al, 2005). In fact, a mutated ‘uncleavable’ full-length
Sema3E, which cannot be targeted by furins and converted into
p61 (Uncl-Sema3E; Fig 1A), did not promote metastasis
formation in experiments based on direct cancer cell injectionSema3E).
B. Migration of MDA-MB435 cancer cells assayed
in Transwell inserts in the presence of 7 nM
Uncl-Sema3E, or 7 nM p61-Sema3E, or mock.
Migrated cells were quantified by staining with
crystal violet and measuring the absorbance at
595 nm (see Materials and Methods Section).
Data are given as average SD of two inde-
pendent experiments performed in duplicate
(n¼ 4).
C. Serum-starved A549 cancer cells were treated
with either purified 7 nM p61-Sema3E, or 7 nM
Uncl-Sema3E, or mock, for 10 min. The induced
association between endogenous PlexinD1
receptor and ErbB2 tyrosine kinase was revealed
by immunoblotting. The data are representative
of three independent experiments yielding
consistent results.
D. A549 carcinoma cells were treated as above, and
total protein lysates were analyzed by immu-
noblotting with phospho-specific antibodies to
detect activated forms of MAPK, as well as with
the respective non-phospho-specific antibody to
provide loading controls.
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236in the circulation (Christensen et al, 2005). Here, we also show
that, in contrast to p61, Uncl-Sema3E does not induce cancer
cell migration (Fig 1B). We have recently reported that the pro-
invasive and pro-metastatic activity of p61 is due to the
association between PlexinD1 and the oncogenic tyrosine-
kinase receptor ErbB2 as well as the induction of ErbB2 tyrosine
phosphorylation and intracellular signalling (Casazza et al,
2010). We therefore asked whether the proteolytic processing of
Sema3Emay be required for its ability to trigger ErbB2 signalling
in cancer cells. Notably, Uncl-Sema3E was unable to induce the
association of ErbB2 with PlexinD1 (Fig 1C, top), nor did it
promote ErbB2 phosphorylation (Fig 1C,middle) or intracellular
mitogen-activated protein kinase (MAPK) signalling (Fig 1D).
Despite this apparent lack of activity, we found that Uncl-
Sema3E is fully capable of binding the receptor PlexinD1 inA
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Figure 2. Uncl-Sema3E antagonizes p61 and blocks its pro-metastatic signal
A. COS cells transfected to express PlexinD1 were probed with alkaline phosphata
incubation with an AP substrate (see Supporting Information Methods). Scale
B. PlexinD1-expressing COS cells (as above) were incubated with AP-labelled p61-
(precisely: 3, 7, 15, 60 nM) (n¼6 for each experimental condition). Equimola
PlexinD1, which was almost abrogated upon excess competition. Statistical sig
absence of Uncl-Sema3E: p¼ 1.3E06; p¼3.2E08; xp¼ 1.4E08; xxp¼ 1.
overexpressing its cognate receptor PlexinB1 provided a specificity control.
C. Serum starved A549 cancer cells were incubated with 7 nM Uncl-Sema3E or
Heregulin-b1 (as positive control) in the presence of Uncl-Sema3E. ErbB2 tyr
D. Migration of A549 and 4T1 cells expressing Uncl-Sema3E or control-EV, assayed
controls.
E. Fluorescently labelled A549 cells, either expressing Uncl-Sema3E or control-EV
later the mice were sacrificed, and the lungs fixed and analyzed under a fluore
the tissue (n¼ 5; see Materials and Methods Section for details). Representat
F. A549 and 4T1 cells expressing Uncl-Sema3E or control-EV were injected intrave
metastatic colonies in the lungs were counted under a stereomicroscope; the g
lungs are also shown, where red arrows indicate some of the metastatic lesio
 2012 EMBO Molecular Medicineanalogy to p61-Sema3E isoform (Fig 2A). Moreover, we found
that Uncl-Sema3E selectively competes with p61 for binding the
receptor in the same nanomolar concentration range (Fig 2B).
We then asked whether Uncl-Sema3E may potentially act as a
dominant-negative molecule by interfering with p61 signalling.
Indeed, ErbB2 transactivation elicited by p61 in A549 cells was
strikingly reduced in the presence of Uncl-Sema3E (Fig 2C).
Furthermore, data shown above in Fig 1C revealed that the basal
level of ErbB2 tyrosine phosphorylation decreased in cells
treated with Uncl-Sema3E, consistent with its functional
competition with endogenous p61.
Altogether, these data suggested that Uncl-Sema3E, by
blocking the transactivation of ErbB2, could interfere with the
invasive-metastatic effect driven by p61-Sema3E. Intriguingly,
earlier studies had tested the activity of full-length uncleavablema3E-AP
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ive images are shown on the right; scale bars: 100mm.
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EMBO Mol Med 4, 234–250 www.embomolmed.org
Research Article
Andrea Casazza et al.Sema3E in non-metastatic 168-FARN mouse mammary carci-
noma cells, which express very low levels of endogenous
Sema3E (Christensen et al, 2005; and Supporting Information
Fig 1). In contrast, we found that p61-Sema3E and the receptor
PlexinD1 are well expressed in several cancer cells, establishing
autocrine signalling circuits, which drive invasion and metas-
tasis (Casazza et al, 2010). Therefore, in order to validate a
potential dominant-negative effect of Uncl-Sema3E in vitro and
in vivo, we ectopically expressed this mutant in two metastatic
cancer cells with autocrine p61 signalling. First, we used 4T1
mousemammary carcinoma cells, which are syngenic with (and
have the same origin as) 168-FARN cells, but were selected for
their strong metastatic behaviour (Aslakson & Miller, 1992);
intriguingly, these cells carry high endogenous levels of Sema3E
(Casazza et al, 2010; also see Supporting Information Fig 1). In
addition, similar experiments were performed in A549 human
lung carcinoma cells, which we also found to depend on
endogenous p61 (Casazza et al, 2010). Uncl-Sema3E over-
expression did not affect endogenous levels of p61-Sema3E
secreted by cancer cells (Supporting Information Fig 2A) nor
formed heterodimeric complexes with p61 (Supporting Infor-
mation Fig 2B and C). Notably, although cancer cell viability
was not impaired by Uncl-Sema3E overexpression (Supporting
Information Fig 3A and B), we found that spontaneous cell
migration was remarkably reduced in both models (Fig 2D).
This was not associated with detectable changes in cellular
phenotype or modified expression of the typical markers of
epithelial–mesenchymal transition (Supporting Information Fig
3C–E), while it could be explained by the reduced activation of
ErbB2 signalling demonstrated above. Moreover, we found that
Uncl-Sema3E dramatically impaired the metastatic potential
of tumour cells in vivo, as observed 48 h after injection of
fluorescently labelled cells in the circulation (Fig 2E) as well as
at later stages by counting macroscopic metastatic colonies in the
lungs (Fig 2F). These results phenocopied those observed upon
ribonucleic acid (RNA) interference (RNAi)-mediated Sema3E
silencing in cancer cells (Casazza et al, 2010) and further
suggested a dominant-negative function of Uncl-Sema3E, antag-
onizing p61-driven metastatic extravasation of tumour cells.
Uncl-Sema3E inhibits integrin-mediated adhesion and
intracellular signalling in endothelial cells
Further investigating the functional relevance of uncleaved
Sema3E, we observed that it could trigger the typical
semaphorin-driven ‘collapsing’ response in COS cells expressing
PlexinD1 (unpublished observation). Moreover, Uncl-Sema3E
strongly and rapidly induced the retraction of cellular processes
and the rounding of human umbilical vein-derived endothelial
cells (HUVEC) (Figure 3A and Supporting Information Movies
1A–C). These effects have been reported for several semaphor-
ins and are currently explained by the inhibitory activity
mediated by plexins on integrin-based focal adhesive complexes
(Barberis et al, 2004). Notably, a recent study showed that
Sema3E triggers integrin-beta1 internalization leading to
reduced cell-substrate adhesion (Sakurai et al, 2010). We
therefore investigated the ability of Uncl-Sema3E to inhibit
integrin function and intracellular signalling in endothelial cells.www.embomolmed.org EMBO Mol Med 4, 234–250We found that as little as 5min of treatment with Uncl-Sema3E
were sufficient to trigger a dramatic disassembly of focal
adhesion complexes (Fig 3B); these structures connect integrins
with the cytoskeleton and are pivotally involved in the
protrusion of cellular processes as well as in cell migration
dynamics. Moreover, the presence of integrin-beta1 molecules
in active conformation on the cell surface was significantly
reduced upon treatment with Uncl-Sema3E (Fig 3C and
Supporting Information Fig 4), further indicating reduced
adhesion to the extracellular matrix. We also found that pre-
treating endothelial cells with antibodies directed against the
active conformation of integrin-beta1, which forcibly stabilizes
cell-substrate adhesion, was sufficient to prevent cell contraction
induced by Uncl-Sema3E (Supporting Information Fig 5A). This
indicated that the loss of cell-substrate adhesion is crucial for the
inhibitory activity of Uncl-Sema3E in endothelial cells. Notably,
several studies underlined that substrate adhesion is a major
requirement for the viability of endothelial cells, and its default
leads to programmed cell death by anoikis, both in culture and
in vivo (reviewed by Cheresh & Stupack, 2008). We found that
focal adhesion disassembly triggered by Uncl-Sema3E further
inhibited downstream intracellular signalling cascades, especially
the activation of focal adhesion kinase (FAK) and the associated
upregulation of phosphorylated MAPK/ERK (Fig 3D). It was
shown previously that molecules interfering with FAK and
subsequent MAPK activation in endothelial cells lead to an
apoptotic response (Lu & Rounds, 2011). In fact, we observed an
increased number of active-caspase 3-positive apoptotic endothe-
lial cells upon treatment with Uncl-Sema3E as assessed by two
independent methods (Fig 3E and F).
Uncl-Sema3E inhibits endothelial cell migration and tube
formation
Consistent with its potent regulatory activity on integrin
function and cytoskeletal dynamics, we found that Uncl-
Sema3E strongly inhibited endothelial cell migration in a
PlexinD1-dependent manner (Fig 4A); notably, this activity
paralleled that of the proteolytic fragment p61 (Casazza et al,
2011). Moreover, we found that this inhibitory effect of
Sema3E in endothelial cells is dependent on the expression of
the intracellular adaptor molecule Rnd2 (Supporting Informa-
tion Fig 5B).We further assessed the activity of Uncl-Sema3E in
HUVEC engaged in vascular tube formation. In fact, HUVEC
grown in vitro on a basement membrane matrix (Matrigel)
undergo spontaneous alignment into hollow tubes, forming
capillary-like networks within 24 h (Grant et al, 1989).
However, we found that endothelial tubule formation and
stability was significantly impaired in the presence of Uncl-
Sema3E compared to untreated cultures (Fig 4B). Moreover,
when HUVEC were grown as spheroids in a three-dimensional
collagen matrix in the presence of basic fibroblast growth
factor (bFGF), they formed elongated sprouts, which were
significantly reduced in the presence of either Uncl-Sema3E or
the proteolytic fragment p61 (Fig 4C). These data further
indicated that full-length uncleaved Sema3E is not an inactive
precursor molecule, since it can elicit a potent PlexinD1-
mediated inhibitory response in endothelial cells. Moreover, 2012 EMBO Molecular Medicine 237
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Figure 3. Uncl-Sema3E inhibits integrin-mediated adhesion and intracellular signalling in endothelial cells.
A. HUVEC were stained with FITC-phalloidin to reveal F-actin (in green) and 4,6-diamidino-2-phenylindole (DAPI) to highlight nuclei. Upon incubation with 7 nM
Uncl-Sema3E for 20 min, endothelial cells totally disassembled F-actin stress fibers, and cellular processes were retracted, leading to the typical collapsed
phenotype (see Barberis et al, 2004). Scale bar: 50mm.
B. HUVEC were treated with 7 nM Uncl-Sema3E for the indicated times (or left untreated) and then subjected to immunofluorescence analysis by staining with
anti-Paxillin antibodies (revealed in red) and with FITC-falloidin to detect F-actin (in green). On the right, images of cellular processes are magnified to reveal
focal adhesions (FA) and the percent fraction of FA-containing cells is indicated aside. Scale bars: 20 and 10mm in the magnified fields shown on the right.
C. The graph summarizes the results of immunofluorescence analysis shown in Supporting Information Fig 4, and indicates the amount of integrin-b1 in active
conformation on the surface of HUVEC, either untreated or treated with 7 nM Uncl-Sema3E for 5 min; n¼ 4 (each condition).
D. HUVEC were treated with 7 nM Uncl-Sema3E for the indicated times (or left untreated) and their protein lysates were subjected to immuno-blotting analysis
with antibodies directed against Y397 phosphorylated focal adhesion kinase (P-FAK), serine/threonine phosphorylated MAPK and AKT and vinculin (as protein
loading control).
E. HUVEC grown on glass coverslips were treated with 7 nM Uncl-Sema3E (n¼4) or with 200 nM staurosporin (STS; n¼ 4) for 1 h, or left untreated (n¼ 4). The
early apoptotic marker activated-caspase 3 was revealed by immunofluorescence (shown in red); nuclei were counterstained with DAPI; scale bar: 50mm. The
graph indicates the average percent fraction of apoptotic cells in each condition SD; p¼ 0.008; p¼ 0.0002 (vs. control).
F. HUVEC were treated with 7 nM Uncl-Sema3E for the indicated times (or left untreated) and then subjected to cytofluorimetric analysis with antibodies
directed against activated-caspase 3. The experiment was repeated three times with consistent results.
238they demonstrated that the endothelial-repelling function of
Sema3E pre-exists to, and it is not significantly blocked by, the
proteolytic processing of the molecule. Taken together, these
findings characterize Uncl-Sema3E as a partial agonist of
PlexinD1 as compared to the cleaved mature p61 fragment. In
fact, Uncl-Sema3E is able to bind to Plexin-D1 and elicits
endothelial cell repulsion and anti-angiogenic activity in vitro,
but unlike p61, it is unable to trigger the ErbB2-dependent
pathway in cancer cells, and instead, it antagonizes this major
signal promoting invasion and metastasis. 2012 EMBO Molecular MedicineUncl-Sema3E inhibits tumour angiogenesis and tumour
growth in vivo
A potential regulatory function of full-length uncleaved Sema3E in
primary tumour development had never been investigated. We
therefore assessed the activity of Uncl-Sema3E in multiple
experimental models of tumour progression in mice. Initially, we
exploited tumorigenic and weakly metastatic humanMDA-MB-435
cancer cells that express PlexinD1 receptor but contain relatively
low endogenous levels of Sema3E (see expression analysis in
Supporting Information Fig 1). Notably, the over-expression ofEMBO Mol Med 4, 234–250 www.embomolmed.org
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Figure 4. Uncl-Sema3E inhibits endothelial cell migration and tube formation.
A. The haptotactic migration of HUVEC was assayed in Transwell inserts. In the presence of Uncl-Sema3E or p61-Sema3E (7 nM) endothelial cells migration was
inhibited, in PlexinD1-dependent manner (PLXND1 knock-down was achieved by shRNA expression, see Materials and Methods Section). Data are given as
average SD of two independent experiments performed in duplicate (n¼ 4).
B. HUVEC were grown in Matrigel-coated wells for 24 h (see Materials and Methods Section) in the presence or absence of purified p61-Sema3E or Uncl-Sema3E.
Representative phase-contrast microscopy images are shown on the left (scale bar: 200mm). The assay was repeated several times (n¼ 4) and quantified by
counting bifurcations of vessel-like tubular structures in multiple microscopic fields (the graph on the right shows mean values SD from at least five separate
wells for each condition).
C. HUVEC spheroids (containing approximately 400 cells each) were implanted in collagen gels, in the presence or absence of bFGF (see Materials and Methods
Section for details). Moreover, either Uncl-Sema3E or p61 (1mg/ml each) were included with bFGF in some of the wells (n¼ indicated in figure below respective
bars). Spheroids were photographed after 24 h (representative images are shown; scale bar: 100mm) and endothelial sprouts were quantified as described
(Shraga-Heled et al, 2007).Uncl-Sema3E did not induce significant changes in the tumour cell
proliferation rate in culture, even upon serum deprivation (Fig 5A
and Supporting Information Fig 3A and B), consistent with our
previous findings concerning p61-Sema3E isoform (Casazza et al,
2010). On the other hand, both Uncl-Sema3E and p61-Sema3E
caused a striking inhibition of tumour growth upon subcutaneous
transplantation of the overexpressing cells in immunodeficient
mice (Fig 5B and C), putatively consistent with a paracrine effect
in the tumour microenvironment. The histological analysis of
explanted tumours actually revealed that Uncl-Sema3E had
strongly reduced vessel density (Fig 5D). This was also confirmed
in tumour samples explanted at an earlier stage when the size of
control and Uncl-Sema3E-expressing xenografts was almost
comparable (Supporting Information Fig 6A), consistent with
the idea that the paracrine anti-angiogenic activity of thiswww.embomolmed.org EMBO Mol Med 4, 234–250molecule was primarily responsible for tumour suppression.
Moreover, we found that Uncl-Sema3E (and p61) impaired
pericyte coverage of blood vessels (Fig 5E and Supporting
Information Fig 6B), leading to reduced vessel functionality and
perfusion (Fig 5F) as well as increased vessel permeability
(Supporting Information Fig 6C). These data prompted us to
investigate a potential regulatory activity of Uncl-Sema3E on
vascular pericyte recruitment. In fact, we found that endothelial
cells exposed to Uncl-Sema3E down-regulated the expression
of PDGF-B, a major factor recruiting mural cells to vessels
(Supporting Information Fig 7A). Moreover, the migration of
primary microvascular pericytes in vitro was significantly
inhibited by Uncl-Sema3E in a PlexinD1-dependent manner
(Supporting Information Fig 7B). Thus, in addition to a direct
inhibitory effect on endothelial cell adhesion, migration and 2012 EMBO Molecular Medicine 239
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Figure 5. Uncl-Sema3E inhibits tumour angiogenesis and tumour growth in vivo.
A. MDA-MB435 cancer cells over-expressing Uncl-Sema3E, or p61-Sema3E, or carrying a non-coding empty vector (EV) were grown in culture for 3 days in 0.5%
FBS. Cell growth was evaluated daily, by staining with crystal violet and quantifying absorbance at 595 nm. Indicated values are the average of two
independent experiments performed in triplicates.
B-C. MDA-MB435 cancer cells carrying Uncl-Sema3E, or p61-Sema3E, or control-EV (as above) were injected subcutaneously into nude mice (n¼5, per each
experimental group). Panel B displays tumour volume growth over time, while panel C shows tumour weight at the end of the experiment. The graph shows
the mean SD of six mice per each experimental condition.
D. The tumours formed by engineered MDA-MB435 (described above) were explanted at the end of the experiment and tissue sections were immunostained for
the endothelial cell marker CD31 to quantify vessel density.
E. Double-staining for CD31 (red) and NG2 (green), endothelial and pericyte markers, respectively, revealed a reduced fraction of pericyte-covered tumour
vessels in Uncl-Sema3E tumours compared to controls (scale bars: 100mm); p¼ 2.6E05; p¼ 1.0E05.
F. Vessel perfusion was assessed upon intravenous injection of FITC-conjugated Lectin 10 min before mouse sacrifice and tumour excision. CD31 was
counterstained in red to reveal endothelial cells (scale bars: 100mm); p¼ 0.018; p¼ 0.0095.
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with pericyte recruitment.
The disruption of vessel networks usually correlates with
deficient tissue oxygenation. In fact, we found that Uncl-
Sema3E-expressing tumours were diffusely hypoxic as revealed
by pimonidazole (PIMO) staining (Fig 6A) and heavily apoptotic
compared to controls (Fig 6B); this likely accounted for the
observed shrinkage of the tumours, as the mitotic index was
not significantly affected by the treatment (Fig 6C). Notably,
tumours expressing Uncl-Sema3E did not give rise to increased
secondary metastatic foci with respect to controls (Fig 6D),
whereas we have previously shown that either wild-type
cleavable Sema3E or the mature fragment p61 are actively
pro-metastatic in vivo (Casazza et al, 2010).EV
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A
B EV
Uncl-Sema3E
p61-Sema3E
EV
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C
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Figure 6. Uncl-Sema3E anti-angiogenic activity leads to tumour hypoxia and
A. Tissue sections from tumours formed by MDA-MB435 control-EV cells, or cells o
(PIMO, green) to reveal hypoxic areas (n¼5; see Materials and Methods Sectio
Data are given as percent fraction of PIMOþ area/total area.
B. Sections of the same tumours as above were immunostained for cleaved caspa
the apoptotic index (number of cleaved Casp3 positive cells/total cell number)
xxxp¼ 1.9E09; xxp¼ 0.0025.
C. Sections of the same tumours as above were analyzed by immunohistochem
counterstaining. No significant difference was detected between samples. Sc
D. Superficial metastatic colonies in the lungs of mice bearing the same tumou
stereomicroscope after airways infusion with ink. Unlike what seen with p61
www.embomolmed.org EMBO Mol Med 4, 234–250RIP-Tag2 (RT2) transgenic mice are a very well characterized
and stereotyped model of pancreatic neuroendocrine sponta-
neous tumorigenesis (Hanahan, 1985). These mice develop
islet carcinomas in a multi-step process characterized by the
temporal appearance of distinctive lesions, including hyperplasia,
followed by the so-called ‘angiogenic switch’ in the angiogenic
islets, eventually accompanied by sporadic appearance of
multiple tumours (Bergers et al, 2000). We therefore subjected
tumour-bearing RT2 mice to the local delivery of affinity-purified
Uncl-Sema3E (see Supporting Information Fig 8) into the
pancreas by means of Alzet osmotic mini-pumps, in order to
assess its activity in inhibiting angiogenesis and regressing
tumour burden. The treatment with Uncl-Sema3E achieved a
remarkable reduction of total tumour burden (Fig 7A) as well asp61-Sema3E Uncl-Sema3E
p61-Sema3E Uncl-Sema3E
EV
Uncl-Sema3E
p61-Sema3E
D
Uncl-Sema3E
CD31 PIMO DAPI
CD31 Caspase3 Act. DAPI
***
P=0.0074
apoptosis.
verexpressing Uncl-Sema3E or p61-Sema3E, were stained with pimonidazole
n) and for the endothelial marker CD31 (red); nuclei were stained with DAPI.
se 3 (green), CD31 (red) and DAPI. Uncl-Sema3E and p61 expression enhanced
. The graph indicates mean values SD (n¼ 5); p¼ 5.9E11; p¼0.0046;
istry to reveal the mitotic nuclear marker Ki67, followed by hematoxilin
ale bars (throughout this figure): 100mm.
rs as above (n¼ 5 per each experimental group) were counted under a
, Uncl-Sema3E did not promote tumour metastatic spreading.
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242of the average number of tumour foci (unpublished observation)
compared to control-treated mice, while tumour cell proliferation
was not significantly affected (Supporting Information Fig 9A).
Importantly, the tumour vessel area was dramatically reduced
(Fig 7B), vessel coverage was impaired (Fig 7C and Supporting0 
10 
20 
30 
40 
50 
60 
0 
10 
20 
30 
40 
50 
60 
70 
N
G
2 
co
at
ed
 v
es
se
ls
 (%
) 
C
To
ta
l t
um
or
 b
ur
de
n 
(m
m
3 )
 
A
Mock 
Uncl-Sema3E 
Sunitinib 
0 
20 
40 
60 
80 
100 
H
yp
ox
ic
 a
re
a 
(%
) Mock Sunitinib 
Endoglin PIMO DAPI 
Uncl-Sema3E 
D
0 
2 
4 
6 
8 
Ve
ss
el
 A
re
a 
(%
) 
3 
5 
7 
B
Mock Sunitinib Uncl-Sema3E 
NG2 CD31 DAPI 
Mock 
Uncl-Sema3E 
Mock 
Uncl-Sema3E 
Sunitinib 
E 
Uncl-Sema3E 
Sunitinib 
Mock Sunitinib 
0 
10 
20 
30 
40 
50 
60 
70 
IT IC1 IC2 
%
 to
ta
l t
um
or
s 
pe
r a
ni
m
al
 
* 
** 
P = 5E-05  
P = 0,0006 
P = 3E-09  
P = 2E-09  
1 
P = 0,0046 
P = 1E-06  
P = 2E-05  
Mock 
Uncl-Sema3E 
Sunitinib 
Mock 
Uncl-Sema3E 
Sunitinib 
Mock 
Uncl-Sema3E 
Sunitinib 
P = 0,0029 
igure 7.F 2012 EMBO Molecular MedicineInformation Fig 9B) and endothelial cell apoptosis was increased
(Supporting Information Fig 9C). As expected, the strong anti-
angiogenic activity mediated by Uncl-Sema3E caused diffuse
tumour hypoxia (Fig 7D). This effect on the primary tumours is
comparable to that reported in the literature upon administrationEMBO Mol Med 4, 234–250 www.embomolmed.org
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~of validated vascular endothelial growth factor (VEGF)-targeted
anti-angiogenic drugs in the same model (Bergers et al, 2003;
Pa`ez-Ribes et al, 2009) as we confirmed in a series of mice treated
in parallel with the tyrosine kinase inhibitor sunitinib (Fig 7A–D).
Notably, it was shown that tumour shrinkage and tissue hypoxia
generated by vessel disruption can trigger ‘escape’ mechanisms
leading to drug resistance, increased local invasion and
metastatic spreading (Casanovas et al, 2005; Ebos et al, 2009;
Pa`ez-Ribes et al, 2009). This was confirmed in our RT2 mice
treated with sunitinib, as in fact primary tumours were locally
more invasive; in contrast, pancreatic tumours treated with Uncl-
Sema3E not only were smaller, but also displayed a partial
reduction of local invasiveness compared to controls (Fig 7E).
Notably, tissue immunostaining revealed that the receptor
PlexinD1 is expressed in both endothelial and tumour cells
(Supporting Information Fig 9D) consistent with the idea that
Uncl-Sema3E could regulate both cell types. Moreover, while the
incidence of tumour-invaded peri-pancreatic lymph nodes aswell
as the volume of lymphonodal foci was dramatically increased in
sunitinib-treated mice, in the presence of Uncl-Sema3E, tumour
lymphatic infiltrationwas not significantly different from controls
(Supporting Information Fig 10A). Notably, lymph node infiltra-
tion is a common finding in RT2 tumours, while distant liver
metastases are observed in only 10–20% of cases (Pa`ez-Ribes
et al, 2009). However, the increased primary tumour invasive-
ness caused by sunitinib further resulted into the formation of
numerous distantmetastasis in the liver, consistentwith previous
findings (Pa`ez-Ribes et al, 2009); in contrast, this was not
observed upon treatment with Uncl-Sema3E, which was
occasionally associated with smaller and isolated liver metas-
tasis, as seen in controls (Supporting Information Fig 10B).
Altogether, these data indicate that RT2 mice treatment with
Uncl-Sema3E achieved striking tumour shrinkage consequent to
vessel disruption, which was not associated with increased local
invasion and metastatic spreading, as observed for sunitinib and
other anti-angiogenic molecules.
Systemic delivery of Uncl-Sema3E suppresses tumour growth
and prevents metastatic spreading
We finally asked whether Uncl-Sema3E could be delivered
systemically in mice as a therapeutic drug to interfere with
tumour progression. To this end, we analyzed multiple overtlyFigure 7. Uncl-Sema3E inhibits angiogenesis and tumour growth in the RIP-T
release locally in the pancreas Uncl-Sema3E (n¼ 14) or mock saline (n¼12) over a
same period (see Materials and Methods Section for details); two independent e
A. Average global tumour burden per mice in different experimental conditions.
B. Vessel area in treated tumours was estimated based on CD31 staining (n¼6
C. Vessel coverage with mural cells was assessed by double staining for NG2 an
D. Hypoxic areas in islet tumours were revealed by staining with pimonidazol (PIM
with the endothelial cell marker Endoglin-CD105, and with DAPI.
E. Primary RT2 tumour invasiveness was assessed by morphometric analysis of
Representative images of the different groups are shown on the right. Uncl-Sem
was ‘encapsulated’ and well separated from the surrounding exocrine tissue (
invasive front was often extensively intercalated with the surrounding norma
encapsulated (IT), microinvasive (IC1) and highly invasive (IC2) carcinomas p
significance of the different relative representation of each tumour histotype in
xxp¼ 1.7E06. Scale bars, throughout the entire figure: 100mm (20mm in m
www.embomolmed.org EMBO Mol Med 4, 234–250metastatic models and applied diverse strategies for the
systemic delivery of Uncl-Sema3E in tumour-bearing mice:
either based on gene transfer in vivo or on the administration of
a purified recombinant protein. Hydrodynamic delivery of
naked DNA expression plasmids in the circulation is commonly
used to achieve transgene expression in mice, especially in the
liver, and sustained plasmatic levels of secreted factors (Liu
et al, 1999). We therefore compared the potential tumour
suppressing activity of wild-type Sema3E that can be freely
processed into p61 and its mutated counterpart Uncl-Sema3E by
intravenously injecting immunodeficient mice with the expres-
sion constructs encoding either protein. The next day, we
transplanted the mice with 4T1 mammary carcinoma cells.
Moreover, we verified by enzyme-linked immunosorbent assay
(ELISA) that the average blood concentration of Sema3E
isoforms in the two groups of treated mice was comparable:
i.e. 185 88mg/ml for Sema3E wt, and 179 75mg/ml for Uncl-
Sema3E (vs. an endogenous level of approximately 6 ng/ml
Sema3E in control mice). Primary tumours grew significantly
less in the presence of either of the two Sema3E isoforms (Fig 8A
and B) and vessel area was comparably reduced (Fig 8C),
consistent with the fact that the proteolytic processing of this
semaphorin does not impact on its anti-angiogenic activity.
However, while metastases were increased with respect to
controls following treatment with wild-type cleavable Sema3E,
they were remarkably reduced in the presence of Uncl-Sema3E
(Fig 8D) consistent with its ability to compete with endogenous
p61. We further validated the tumour suppressing and
anti-metastatic activity of systemic Uncl-Sema3E in another
metastatic tumour model expressing endogenous Sema3E,
i.e. lung carcinoma cells A549, achieving similar results
(Supporting Information Fig 11). Notably, a histopathological
analysis of liver, kidneys, heart and adrenal glands ofmice treated
with Uncl-Sema3E (delivered by different approaches) did
not reveal significant signs of toxicity or any differences to
tissues of mock-treated animals (Supporting Information Fig 12).
In order to compare the effect of Uncl-Sema3E with that of a
validated anti-angiogenic molecule, we exploited twometastatic
tumour models characterized by different responsiveness
to VEGF-targeted anti-angiogenic therapy. In particular, 4T1
mammary carcinoma cells are highly responsive to anti-
VEGF(R) treatments, which effectively leads to tumourag2 model. Alzet minipumps were implanted in 12-week-old RT2 mice to
period of 2 weeks; other mice were treated orally with sunitinib (n¼ 8) for the
xperiments were performed, yielding consistent results.
, per each experimental group).
d CD31 (n¼6).
O, see Materials and Methods Section; n¼ 6); the same sections were costained
H&E stained sections, as previously reported (Pa`ez-Ribes et al, 2009).
a3E treated tumours often displayed a non-invasive phenotype: i.e. the tumour
delimited by a dotted line). In contrast, in sunitinib-treated mice the tumour
l exocrine tissue. The graph on the left indicates the average fraction of
er mice in each experimental condition (n¼ 8). We assessed the statistical
drug-treated versus mock control mice; p¼ 0.003; p¼0.007; xp¼ 6.1E05;
agnified insets in panel C).
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244shrinkage (Fischer et al, 2007); in contrast, it has been shown
previously that tumours formed by Lewis Lung Carcinoma Cells
(LLc) are refractory to this therapeutic approach (Shojaei et al,
2007). We therefore delivered complementary DNA (cDNA)
constructs encoding either a soluble VEGF trap consisting of the
extracellular portion of VEGFR2 (sFlk1), Uncl-Sema3E or mock
control into immunodeficient mice. These mice were then
randomized into two groups for each construct and transplanted
with either 4T1 or LLc cells the day after hydroporation.
The plasma levels of either molecule were comparable
between mice carrying different models, as assessed by
ELISA (Table 1), and the growth of 4T1 tumours was remarkably
inhibited in the presence of both anti-angiogenic factors
(Fig 9A and B). However, while LLc tumours were insensitive
to anti-VEGF therapy (as expected), their growth was drama-
tically impaired by Uncl-Sema3E (Fig 9D and E), consistent
with the direct inhibitory activity of this molecule in endothelial
cells. Notably, vessel density was remarkably reduced in
LLc tumours treated with Uncl-Sema3E, while it was compar-
able to controls in the presence of sFlk1 (Fig 9G). Upon
analyzing the metastatic dissemination at the end of the
experiment, we found that tumour shrinkage elicited by sFlk1
was accompanied by an increased number of lung metastasis
(Fig 9C and F). In contrast, the tumour suppressing activity of
Uncl-Sema3E was coupled with a reduction of metastatic
dissemination compared to controls in both models (Fig 9C
and F), indicating that it is a valuable therapeutic tool to treat0
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Figure 8. Systemic delivery of Uncl-Sema3E achieves a concomitant inhibitio
A-D. cDNA constructs expressing either wild-type processable Sema3E, or Uncl-Se
Methods Section), achieving systemic delivery of the proteins in the circula
implanted subcutaneously in the engineered mice (n¼5, per each experime
and tumour angiogenesis (revealed by CD31 staining, panel C; scale bar: 100m
significantly reduced in the presence of Uncl-Sema3E, wild-type Sema3E e
 2012 EMBO Molecular Medicinetumours independently from their responsiveness to anti-VEGF
drugs.
Finally, we tested the therapeutic efficacy of affinity-purified
Uncl-Sema3E molecule administered systemically to tumour-
bearing mice. Mice were transplanted orthotopically with 4T1
highly metastatic tumour cells and, as soon as developing
palpable tumours (4–5 days after transplantation), they were
treated i.p. with 30mg/kg of purified Uncl-Sema3E three times/
week for 18 days; the same amount of albumin was
administered in control mice. Importantly, blood counts as
well as liver and kidney markers were not altered in tumour-
bearing mice treated with Uncl-Sema3E compared to controls
(Supporting Information Fig 13A). Moreover, experiments
performed in young healthy mice revealed that the systemic
delivery of Uncl-Sema3E did not interfere with body growth or
mouse behaviour (Supporting Information Fig 13B and
unpublished observations), further suggesting that this treat-
ment does not produce major adverse side effects. The systemic
delivery of purified Uncl-Sema3E strikingly inhibited tumour
growth (Fig 10A and B). Moreover, this treatment efficiently
reduced metastasis formation (Fig 10C). Notably, Uncl-Sema3E
inhibited tumour growth in vivo independently from PlexinD1
expression in cancer cells, as demonstrated by gene knock down
experiments (Supporting Information Fig 14). This indicates
that the activity of Uncl-Sema3E in the microenvironment is
pivotal for the inhibition of tumour growth. Notably, primary
tumours formed by PlexinD1-depleted cells are basally lessmock
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Table 1. Protein concentration in the sera of tumor-bearing mice
(mg/ml) LLC 4T1
sFLK-1 315.2W72.7 271.2W37.2
Uncl-Sema3E 212.4W22.8 179.8W8.7
Protein concentration of sFLK-1 and Uncl-Sema3E in the sera of (LLc or 4T1
tumor-bearing) mice subjected to gene hydroporation (mean values WSD,
assessed by ELISA).metastatic due to the impairment of autocrine p61 signalling
(Casazza et al, 2010); thus, the dominant-negative anti-
metastatic effect of Uncl-Sema3E cannot be seen in tumours
lacking expression of the implicated receptor PlexinD1 in cancer
cells. In sum, either the removal of PlexinD1 receptor in tumour
cells or the systemic delivery of the p61-competing molecule
Uncl-Sema3E similarly achieved a significant reduction of the
metastatic spreading in vivo.
In conclusion, our data show that the systemic delivery of an
uncleavable full-length isoform of Sema3E inhibits tumour0
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Figure 9. Tumours refractory to VEGF-blockade are efficiently inhibited by sy
A-F. The expression of either the validated VEGF-trap molecule sFlk1 or Uncl-Sem
hydroporation (see Materials and Methods Section). The concentration of pro
Mice treated with either of the two anti-angiogenic molecules were random
(VEGF-inhibitor responsive) or LLc (VEGF-inhibitor non-responsive) cancer cell
growth of 4T1 and LLc tumours over time, respectively (statistical significance
4T1 and LLc tumour burden, respectively. Vessel density is shown in panel
metastasis is shown in panels C and F.
www.embomolmed.org EMBO Mol Med 4, 234–250angiogenesis and tumour growth, while blocking the metastatic
dissemination of cancer cells.DISCUSSION
Due to their emerging role in tumour angiogenesis, tumour
growth and metastasis, semaphorins appear as promising
targets for strategies aimed at interfering with cancer progres-
sion. In particular, we have recently demonstrated that Sema3E
expression in human tumours correlates with the metastatic
progression (Casazza et al, 2010). This is explained by an
autocrine signalling mechanism in cancer cells, implicating
the receptor PlexinD1 and the associated oncogenic tyrosine
kinase ErbB2. Notably, Sema3E was furthermore described as
endothelial-repelling cue regulating angiogenesis (Casazza et al,
2010; Fukushima et al, 2011; Gu et al, 2005; Kigel et al, 2008;
Sakurai et al, 2010). These multiple functional activities ofM
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Figure 10. Systemic delivery of purified Uncl-Sema3E suppresses tumour growth and prevents metastatic spreading.
A-C. 4T1 cancer cell were orthotopically transplanted into the mammary fat pad of nude mice. Four days after transplant, mice bearing palpable tumours were
randomized and divided into two groups (n¼8, each group); control group was treated with 30 mg/kg of purified Uncl-Sema3E, while the other was treated
with the same concentration of bovine albumin (mock negative control). The treatment with purified Uncl-Sema3E impaired the growth of orthotopic
tumours (A and B) and the formation of spontaneous lung metastasis (C).
246Sema3E are currently explained by cell context-specific signal-
ling cascades. In addition, Sema3E is subject to regulation by
furin-like pro-protein convertases. These proteolytic enzymes,
particularly abundant in advanced invasive and metastatic
cancers (Bassi et al, 2005), are responsible for converting full-
length Sema3E into the smaller fragment p61. We have shown
here that this process reveals an otherwise concealed signalling
function of Sema3E, i.e. the ability to induce association of
PlexinD1 with the oncogenic tyrosine kinase ErbB2 and to
trigger its intracellular signalling cascade. In fact, while full-
length uncleaved Sema3E and the p61 fragment can both bind
to the extracellular domain of PlexinD1, the former cannot
induce the formation of a complex with ErbB2, likely due
to steric hindrance by the large immunoglobulin-like domain
that is removed upon proteolytic cleavage. As a consequence,
Uncl-Sema3E cannot induce cancer cell migration and is
devoid of pro-metastatic effects. We have reported previously
that in tumours, the balance between precursor full-length
Sema3E and p61 is commonly tilted in favour of the pro-
metastatic fragment (Casazza et al, 2010). Thus, while cancer
cells may convert a larger fraction of precursor-Sema3E into pro-
metastatic p61, the treatment with Uncl-Sema3E could tilt the
balance in the opposite direction by competing for receptor
binding.
In addition and contrary to previous assumptions, here we
showed that uncleaved full-length Sema3E is not at all an
inactive molecule. In fact, endothelial cells treated with Uncl-
Sema3E undergo cell-substrate detachment, cell repulsion and
the typical collapsing response, depending on the PlexinD1
signalling cascade. This means that, unexpectedly, the proteo-
lytic processing of Sema3E has no role in regulating its inhibitory
activity in endothelial cells. Thus, in this study, for the first time,
we could dissect the two distinctive signalling functions
mediated by Sema3E in cancer cells and endothelial cells, by
exploiting a mutated isoform resistant to furin-mediated
cleavage. The functional relevance in physiology of non-cleaved
full-length Sema3E precursor versus the p61 fragment is not
addressed in this study, but it would deserve future investiga- 2012 EMBO Molecular Medicinetion, e.g. by usingmolecular genetics to knock-in an uncleavable
Sema3E allele in the mouse genome.
It is well established that angiogenesis plays a pivotal role for
tumour growth, and disrupting the tumour vasculature has
become a common strategy to interfere with cancer progression.
For instance, inhibitors of the prominent VEGF signalling
pathway supporting angiogenesis are applied in the treatment of
human cancers; yet resistance to anti-VEGF therapy has been
observed in both preclinical and clinical trials (Rapisarda &
Melillo, 2009), seemingly due to the involvement of additional/
alternate pro-angiogenic signals. Notably, we found that Uncl-
Sema3E not only inhibited endothelial cells in culture, but its
ectopic expression strongly impaired tumour angiogenesis and
tumour growth in multiple preclinical tumour models in mice,
either spontaneously or generated by cancer cell transplanta-
tion. In fact, upon treatment with Uncl-Sema3E, tumour
vasculature was reduced and lacked appropriate coverage with
mural cells; moreover, tumours became diffusely hypoxic and
apoptotic. Notably, we found that Uncl-Sema3E inhibited
tumour growth in vivo even upon PlexinD1 knockdown in
cancer cells, consistent with that its activity in the microenvir-
onment is essentially responsible for this effect.
The anti-angiogenic and tumour growth inhibitory effect
attained by Uncl-Sema3E in mice seemed to be comparable or
superior to that achieved by therapeutic concentrations of a
validated VEGF trap or a VEGFR2 inhibitor. Moreover, Uncl-
Sema3E effectively suppressed the growth of a tumour model
non-responsive to VEGF-targeted anti-angiogenic therapy. This
is consistent with the fact that this molecule carries an intrinsic
inhibitory activity in endothelial cells, mediated by PlexinD1,
rather than acting by blocking the pro-angiogenic function of
VEGF or another specific factor. Interestingly, we found that
integrin-mediated adhesion to the extracellular matrix was
rapidly impaired in endothelial cells treated with Uncl-Sema3E;
thereby, focal adhesions were disassembled and the actin
cytoskeleton rearranged leading to the typical ‘collapsed’
phenotype. These findings are consistent with previous data
indicating that inhibitory signals mediated by semaphorinsEMBO Mol Med 4, 234–250 www.embomolmed.org
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the monomeric GTPase R-Ras, stabilizing integrin active
conformation, and on the expression of the regulatory molecule
Rnd2 (Casazza et al, 2010; Oinuma et al, 2004). Moreover, a
recent report indicated that PlexinD1 activation by Sema3E
elicits integrin-beta1 endocytosis mediated by the monomeric
GTPase Arf6 (Sakurai et al, 2010). Now we found that the
impairment of integrin function elicited by Uncl-Sema3E in
endothelial cells correlated with a reduced activation of the
signal transducer FAK and of its downstream effector MAPK.
Interestingly, endothelial cells are strictly dependent on these
consensus signals mediated by the extracellular matrix for
adhesion, migration and survival (Cheresh & Stupack, 2008),
which may explain their overt collapsing response to Uncl-
Sema3E stimulation. Notably, reduced substrate adhesion
and FAK inactivation have been reported to induce endothelial
cell apoptosis (reviewed by Lu & Rounds, 2011). In line with
these data, we found that endothelial cells treated with
Uncl-Sema3E show an increased tendency to undergo pro-
grammed cell death, likely due to impaired cell-substrate
adhesion (anoikis).
It was demonstrated that tumour shrinkage induced by anti-
angiogenic drugs blocking VEGF signalling correlates with a
severely hypoxic environment, which leads to increased cancer
cell invasiveness and distant metastasis (Ebos et al, 2009; Pa`ez-
Ribes et al, 2009). In contrast, the anti-angiogenic activity of
Uncl-Sema3E (even when associated with tumour hypoxia) did
not induce invasion and metastasis, suggesting that this
molecule might concomitantly control cancer cell behaviour.
Notably, a wide range of human tumour cells express PlexinD1
(Casazza et al, 2010; Roodink et al, 2005, 2009) and depend on
autocrine p61-Sema3E signalling for invasiveness and meta-
static spreading in vivo (Casazza et al, 2010). Here, we showed
that p61/PlexinD1 signalling in tumour cells can be conveni-
ently blocked by the competitor molecule Uncl-Sema3E,
hindering invasiveness and metastasis in preclinical models.
In fact, Uncl-Sema3E not only inhibited tumour growth without
inducing metastasis formation, but its activity effectively
reduced the spreading of multiple highly metastatic cells to
distant organs. Uncl-Sema3E could not block proximal lymph
node infiltration by tumour cells in RT2 mice. This is consistent
with our analysis of gene expression in human primary
colorectal tumours indicating that elevated Sema3E levels did
not correlate with the colonization of loco-regional lymph
nodes, but they significantly correlated with the metastatic
spreading to the liver and with patient’s survival (Casazza et al,
2010). Moreover, this is in keeping with a major role of p61-
PlexinD1 signalling in cancer cell transmigration through
endothelial layers and hematogenous metastatic dissemination
in experimental models (Casazza et al, 2010).
We have validated the tumour-suppressing activity of Uncl-
Sema3E through multiple delivery approaches in preclinical
models in mice including the systemic administration of a
purified molecule. The effective Uncl-Sema3E concentrations
achieved in the blood of mice subject to systemic delivery are in
the low-micromolar range, similar to those applied for the
validated VEGF-trap sFlk1, and they did not induce appreciablewww.embomolmed.org EMBO Mol Med 4, 234–250adverse effects. Notably, while PlexinD1 is widely distributed in
human tumours, it is expressed at low levels in normal adult
tissues (Roodink et al, 2005). In fact, several lines of evidence
indicate that plexin-D1 expression is dynamically regulated
during development and in the adult, and most prominently
associated with actively growing vessels. For instance, a very
recent study nicely showed the specific expression of PlexinD1
in tip cells of developing vessels in the retina and proposed that
its expression is induced in these cells by VEGF-VEGFR2
signalling (Kim et al, 2011). Moreover, PlexinD1 expression was
shown to increase in endothelial cells upon ischemia-induced
neovascularization (Fukushima et al, 2011), and it was typically
found expressed in tumour vessels but not in normal quiescent
adult vasculature (Roodink et al, 2005).
In sum, our study demonstrates in vitro aswell as in preclinical
models inmice, that the geneticallymodified semaphorin isoform
Uncl-Sema3E is usefully endowed with a double-tiered activity
against cancer: on one side it strongly impairs tumour
angiogenesis suppressing tumour growth, on the other it
efficiently inhibits the invasive and metastatic behaviour of
cancer cells mediated by Sema3E. Since tumour hypoxia can
promote invasion and metastasis, anti-angiogenic drugs may not
be the risk-free stand-alone therapeutic approach they were
hoped to be. Thus, scientists are now interested in finding drug
combinations, which can associate anti-angiogenic molecules
with others capable of blocking any ensuing invasive and
metastatic spreading of cancer cells. In this perspective, Uncl-
Sema3E appears to be ideally endowed with both anti-angiogenic
and anti-metastatic activities, since it can concomitantly act in the
tumour vasculature and in cancer cells. In conclusion, our data
suggest that both cancer cells and the supporting vasculature
could be targeted in several tumours by using Uncl-Sema3E, a
novel potent tumour suppressor molecule, inhibiting neo-
angiogenesis while preventing invasion and metastasis.MATERIALS AND METHODS
Fluorescent labelling of living cells
A549 cells were incubated with 10mM CFDA SE Vybrant1 cell tracer
(Molecular Probes) for 150 at 378C, then the loading solution was
replaced with fresh prewarmed medium and the cells incubated for
further 30min at 378C before harvesting.
Endothelial tube formation assay
This assay was previously described (Grant et al, 1989). Briefly, HUVEC
were seeded in 48-well tissue culture plates (2104 cells per well)
coated with 150ml Matrigel in HUVEC growth medium. After 24h in the
presence or absence of either purified p61-Sema3E or Uncl-Sema3E
(2mg/ml each), the wells were photographed using phase-contrast
microscopy, and the assay was quantified by counting tube bifurcations
in seven independent fields per each experimental condition.
Endothelial spheroids sprouting assay
Spheroids containing 400 cells each were prepared by the hanging
drop method (Laib et al, 2009) from cultured HUVEC. Spheroids were
harvested and implanted in collagen gels in the presence or absence of 2012 EMBO Molecular Medicine 247
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The paper explained
PROBLEM:
Angiogenesis plays an important role in the growth and
spreading of cancer. New blood vessels ‘feed’ the cancer cells
with oxygen and nutrients, allowing the tumour to grow, invade
nearby tissues, spread to other organs, and form new metastatic
colonies. Ideally, anti-angiogenic therapies are aimed at starving
cancer cells and induce tumour regression. However, recent
studies have shown that current anti-angiogenic drugs seem to
promote a rebound effect, leading to even more invasive cancer
growth and increased metastasis. In fact, these molecules attack
the vasculature without controlling the invasiveness of cancer
cells.
RESULTS:
We studied a mutated form of Semaphorin 3E (Uncl-Sema3E),
which acts as a partial agonist of the specific receptor PlexinD1.
On one hand, Uncl-Sema3E inhibits endothelial cells and
efficiently hampers tumour angiogenesis and tumour growth.
At the same time, this molecule competes with a metastasis-
promoting isoform of Sema3E active in cancer cells, and
inhibits invasiveness and metastatic dissemination. We
demonstrated in multiple preclinical mouse models that the
systemic delivery of Uncl-Sema3E induces tumour shrinkage
(comparable to VEGF inhibitors or possibly better) and
concomitantly prevents cancer cell invasion and metastatic
spreading.
IMPACT:
This study shows for the first time that the molecule Uncl-Sema
3E could be considered a new-generation anti-cancer drug,
capable to target both endothelial and tumour cells, concomi-
tantly blocking vessel-borne nutrient supply and the ability of
cancer cells to escape and form metastasis.
248bFGF (10ng/ml). Moreover, either Uncl-Sema3E or p61 (1mg/ml each)
were included with bFGF in some of the wells. Spheroids were
photographed after 24 h and sprouts formation assessed and
quantified as previously described (Shraga-Heled et al, 2007).
Transplanted tumour models in mice
In vivo studies were conducted in 6–8 weeks old immunodeficient mice
(Charles River Laboratory Lecco, Milan, Italy). Unless otherwise
indicated, in each experiment, we analyzed six tumours per each
condition. For subcutaneous tumour models, depending on cell lines,
2106 MDA-MB-435, 8106 A549, 5105 4T1 cells or 2106 LLc
cells were injected into the right posterior flank of anaesthetized
animals. Tumour size was measured externally every 2 days using
a caliper, and tumour volume was estimated using the equation: V¼4/
3p (d/2)2D/2, where d is the minor tumour axis and D is the major
tumour axis. Mice were sacrificed after 4–6 weeks from transplant, as
indicated, and tumours were weighted after dissection. Superficial
pulmonary metastases were contrasted by black India-ink airways
infusion, and counted on dissected lung lobes under a stereoscopic
microscope. For orthotopic transplant of breast carcinoma cells, 1106
4T1 cells resuspended in 40ml phosphate-buffered saline were injected
into the second mammary fat pad of anesthetized female mice. Tumour
growth and spontaneous lung metastasis were analyzed as above. For
experimental metastasis assays, depending on cell lines, 4.5106 A549
or 2105 4T1 cells were injected into lateral mice tail vein; cell
colonies were scored in the lung by black India-ink airways infusion.
Short-term metastatic extravasation of fluorescent cancer cells in the
lungs was quantified by analyzing five pairs of lungs for each
experimental group (at least five independent microscopic fields each)
with ImageJ software. The statistical significance of results was verified
by calculating p values with Student’s t-test. Animal procedures had
been approved by the Ethical Commission of the University of Torino,
Italy, and by the Italian Ministry of Health. 2012 EMBO Molecular MedicineSystemic protein delivery by naked DNA hydroporation
in vivo
In vivo gene transfer of expression constructs leading to secretion of
wild-type Sema3E, Uncl-Sema3E or sFlk1 (Fischer et al, 2007; Van de
Veire et al, 2010) proteins in mice was achieved by naked DNA
hydrodynamic delivery of naked DNA, as previously described (Liu et al,
1999). Briefly, immunodeficient mice were injected in the tail vein
with 50mg of the indicated plasmid DNA in 2.5ml of Ringer Solution,
over a time of 7 s. One day after hydroporation, tumour cells were
subcutaneously implanted in mice. Proteins concentration in the
circulating blood was determined by ELISA using anti-VEGFR-2 (for
sFlk1) and anti-Sema3E specific immunoassays (R&D Systems),
according to manufacturer’s protocols.
Experiments in RIP-Tag2 mouse model
Generation of RT2 mice as a model of pancreatic b-cell carcinogenesis
has been reported previously (Hanahan, 1985), and exploited for other
studies in our lab (Maione et al, 2009). Alzet osmotic minipumps
(2002 model, Charles River Laboratories) were used to accomplish
local delivery of Uncl-Sema3E in the pancreas of experimental mice
between 12 and 14 weeks of age (see Supporting Information
Methods for details). Sunitinib L-malate (Axon Medchem BV) was
administered to mice daily by oral gavage, at a dose of 40mg/kg. Total
tumour burden was quantified by measuring with a caliper and
estimating the volume of individually excised macroscopic tumours
(>1mm3) with the formula: V¼ a b20.52, where a and b
represent the longer and shorter diameter of the tumour, respectively.
Statistical analysis
Data are reported in graphs as mean values SD (indicated by scale
bars). The number of independent samples analyzed (N) is indicated in
figure legends. Statistical significance was evaluated by unpaired
Student’s t-test (or by Anova-2way test for line graphs), with referenceEMBO Mol Med 4, 234–250 www.embomolmed.org
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Andrea Casazza et al.to respective controls (unless otherwise indicated) and expressed as p
values within figures or in figure legends.Author contributions
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